Comparison of high- versus low-tissue affinity ACE-inhibitor treatment on circulating aldosterone levels in patients with chronic heart failure

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 8, Issue 4, 2007, Pages 200-204

  Vittorio, Timothy J ^a   Ahuja, Kartikya ^a   Kasper, Michael ^b   Turalic, Haris ^a   Tseng, Chi Hong ^b   Jorde, Ulrich P ^c   Gor, Chirayu ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

ACE inhibitor; Aldosterone; High affinity; Low affinity; Renin angiotensin system

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POTASSIUM; SODIUM; SPIRONOLACTONE; TRANDOLAPRIL;

AGE; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FLUID BALANCE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAXIMUM TOLERATED DOSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; STANDARDIZATION; STEADY STATE;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENALAPRIL; HEART FAILURE; HUMANS; INDOLES; MALE; MIDDLE AGED;

EID: 38649094901     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2007.025     Document Type: Article

References (19)

1. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
2. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
3. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
4. Jorde UP, Vittorio TJ, Dimayuga CA et al. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure. Am J Cardiol 2004;94:1501-05.
5. Hornig B, Arakawa N, Haussmann D et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 98:2842-8.
6. Ruzicka M, Skarda V, Leenen FH. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 1995;92:3568-73.
7. Mori T, Nishimura H, Okabe M et al. Cardioprotective effects of quinapril after myocardial infarction in hypertensive rats. Eur J Pharmacol 1998;348:229-34.
8. Fornes P, Richer C, Pussard E et al. Beneficial effects of trandolapril on experimentally induced congestive heart failure in rats. Am J Cardiol 1992;70:43D-51D.
9. Richer C, Mulder P, Fornes P et al. Long-term treatment with trandolapril opposes cardiac remodeling and prolongs survival after myocardial infarction in rats. J Cardiovasc Pharmacol 1992; 20:147-56.
10. Okumura Y, Nasa Y, Sanbe A et al. Effects of long-term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure. J Card Fail 1996;2:301-10.
11. Chien Y, Frohlich ED, MacPhee AA et al. Quinaprilat increases total body vascular compliance in rats with myocardial infarction. J Cardiovasc Pharmacol 1992;19:430-4.
12. Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004; 84:489-539.
13. Anderson TJ, Elstein E, Haber H et al. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-6.
14. Lyons D, Webster J, Benjamin N. Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997; 51:373-8.
15. Jorde UP, Ennezat PV, Lisker J et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-6.
16. Jorde UP, Vittorio T, Katz SD et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106:1055-7.
17. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45.
18. van de Wal RM, Plokker HW, Lok DJ et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006;106:367-72.
19. Watanabe K, Ma M, Wen J et al. Comparative effects of quinapril with enalapril in rats with heart failure. Pharmacology 2004; 71:157-61.